Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shenzhen Fushan Biotech Co. Ltd. manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are handled by 2 distinct examiners across multiple art units. Jennifer Lynn Cain is the busiest examiner for the company, with 1 pending office action. The distribution of actions across 2 distinct art units suggests that the company's biotechnology interests are divided between different technical specialties.
For practitioners, this distribution requires managing distinct prosecution timelines and examiner expectations across the biotechnology sector. The lack of concentration in a single art unit reflects a diversified approach to the company's current biological intellectual property developments. With 2 distinct examiners involved, the company's prosecution is decentralized across multiple individuals at the patent office, requiring coordination across different examination groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CAIN, JENNIFER LYNN | 1 | 45.0% | +70.0% |
| CRUM, MARY ABOU NADER | 1 | 40.4% | +65.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17606145 | COMPOSITION CONTAINING GLUCORAPHANIN AND USE THEREOF | CRUM, MARY ABOU NADER | 22d overdue |
| 18609554 | STABLE RELEASE NUTRITIONAL TARGETING COMPOSITION AND ITS USE | CAIN, JENNIFER LYNN | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18609554 | STABLE RELEASE NUTRITIONAL TARGETING COMPOSITION AND ITS USE | CAIN, JENNIFER LYNN | 1655 | §103 | Final Rejection | — | Pending | Mar 19, 2024 |
| 17606145 | COMPOSITION CONTAINING GLUCORAPHANIN AND USE THEREOF | CRUM, MARY ABOU NADER | 1657 | §103 | Final Rejection | 22d overdue | Pending | Oct 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial